Patents by Inventor Shaoling Li

Shaoling Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYNTHESIS OF RAS INHIBITORS
    Publication number: 20240383920
    Abstract: The present invention relates to Ras inhibitors and to methods for preparing Ras inhibitors.
    Type: Application
    Filed: April 12, 2024
    Publication date: November 21, 2024
    Inventors: Shaoling LI, Yi Ll, Paul LOBBEN, Ross WANG, Steve BALLMER, Xiaojun HUANG
  • SYNTHESIS OF RAS INHIBITORS
    Publication number: 20240368190
    Abstract: The present invention relates to Ras inhibitors and to methods for preparing Ras inhibitors.
    Type: Application
    Filed: April 12, 2024
    Publication date: November 7, 2024
    Inventors: Shaoling LI, Suresh Manthati, Ross Wang, Steve Ballmer, Xiaojun Huang
  • CRYSTALLINE FORMS OF RAS INHIBITORS, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USE THEREOF
    Publication number: 20240352038
    Abstract: The disclosure features crystalline forms of Ras inhibitors, pharmaceutical compositions thereof, and their uses in the treatment of cancers.
    Type: Application
    Filed: April 12, 2024
    Publication date: October 24, 2024
    Inventors: Shaoling LI, Suresh Manthati, Kang-Jye Chou, Jun Huang, Xiaojun Huang
  • CRYSTALLINE FORMS OF RAS INHIBITORS, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USE THEREOF
    Publication number: 20240352036
    Abstract: The disclosure features crystalline forms of Ras inhibitors, pharmaceutical compositions thereof, and their uses in the treatment of cancers.
    Type: Application
    Filed: April 12, 2024
    Publication date: October 24, 2024
    Inventors: Shaoling LI, Paul Lobben, Kang-Jye Chou, Jun Huang, Xiaojun Huang
  • PROCESS FOR PREPARING SHP2 INHIBITORS
    Publication number: 20240182485
    Abstract: Provided herein are methods for preparing an SHP2 inhibitor and intermediates useful therein.
    Type: Application
    Filed: June 15, 2023
    Publication date: June 6, 2024
    Inventors: Mickaël ARNOLD, Steven G. BALLMER, Céline GARNIER, Jean-Pierre LESZCZAK, Shaoling LI
  • SYNTHESIS OF RAPAMYCIN ANALOG COMPOUNDS
    Publication number: 20240174615
    Abstract: The present disclosure relates to novel methods for preparing rapamycin analog compounds, as well as to related intermediates useful in such methods.
    Type: Application
    Filed: October 6, 2023
    Publication date: May 30, 2024
    Inventors: Steven G. BALLMER, Xiaojun HUANG, Shaoling LI
  • Combination dosage form of a mu opioid receptor antagonist and an opioid agent
    Patent number: 11452723
    Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: September 27, 2022
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Shaoling Li, Manshiu Leung, Hao Zhang, Venkat R. Thalladi, Yun Mo
  • SOLID FORMS OF {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, A SHP2 INHIBITOR
    Publication number: 20220298159
    Abstract: The present disclosure relates to crystalline solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, or a pharmaceutically acceptable salt thereof, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: November 29, 2021
    Publication date: September 22, 2022
    Applicant: Revolution Medicines, Inc.
    Inventors: Shaoling LI, Steven G. BALLMER
  • Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor
    Patent number: 11220501
    Abstract: The present disclosure relates to crystalline solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, or a pharmaceutically acceptable salt thereof, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: January 11, 2022
    Assignee: Revolution Medicines, Inc.
    Inventors: Shaoling Li, Steven G. Ballmer
  • SOLID FORMS OF {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, AN SHP2 INHIBITOR
    Publication number: 20210253574
    Abstract: The present disclosure relates to crystalline solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, or a pharmaceutically acceptable salt thereof, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: February 26, 2021
    Publication date: August 19, 2021
    Inventors: Shaoling LI, Steven G. BALLMER
  • COMBINATION DOSAGE FORM OF A MU OPIOID RECEPTOR ANTAGONIST AND AN OPIOID AGENT
    Publication number: 20210161884
    Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.
    Type: Application
    Filed: February 8, 2021
    Publication date: June 3, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Shaoling Li, Manshiu Leung, Hao Zhang, Venkat R. Thalladi, Yun Mo
  • TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF
    Publication number: 20210113541
    Abstract: A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.
    Type: Application
    Filed: December 21, 2020
    Publication date: April 22, 2021
    Inventors: Subramanian S. VENKATRAMAN, Shaoling LI, Robert M. GALE, Jane STEPIC, William W. VAN OSDOL
  • Combination dosage form of a mu opioid receptor antagonist and an opioid agent
    Patent number: 10946009
    Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: March 16, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Shaoling Li, Manshiu Leung, Hao Zhang, Venkat R. Thalladi, Yun Mo
  • TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF
    Publication number: 20200289488
    Abstract: A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.
    Type: Application
    Filed: May 28, 2020
    Publication date: September 17, 2020
    Inventors: Subramanian VENKATRAMAN, Shaoling LI, Robert M. GALE, Jane STEPIC, William W. VAN OSDOL
  • TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF
    Publication number: 20200054619
    Abstract: A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.
    Type: Application
    Filed: October 24, 2019
    Publication date: February 20, 2020
    Inventors: Subramanian VENKATRAMAN, Shaoling LI, Robert M. GALE, Jane STEPIC, William W. VAN OSDOL
  • COMBINATION DOSAGE FORM OF A MU OPIOID RECEPTOR ANTAGONIST AND AN OPIOID AGENT
    Publication number: 20190321350
    Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 24, 2019
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Shaoling Li, Manshiu Leung, Hao Zhang, Venkat R. Thalladi, Yun Mo
  • Combination dosage form of a mu opioid receptor antagonist and an opioid agent
    Patent number: 10369142
    Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: August 6, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Shaoling Li, Manshiu Leung, Hao Zhang, Venkat R. Thalladi, Yun Mo
  • Transdermal Administration Of Fentanyl And Analogs Thereof
    Publication number: 20190167655
    Abstract: A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 6, 2019
    Inventors: Subramanian VENKATRAMAN, Shaoling Li, Robert M. Gale, Jane Stepic, William W. Van Osdol
  • COMBINATION DOSAGE FORM OF A MU OPIOID RECEPTOR ANTAGONIST AND AN OPIOID AGENT
    Publication number: 20180050028
    Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.
    Type: Application
    Filed: October 31, 2017
    Publication date: February 22, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Shaoling Li, Manshiu Leung, Hao Zhang, Venkat R. Thalladi, Yun Mo
  • COMBINATION DOSAGE FORM OF A MU OPIOID RECEPTOR ANTAGONIST AND AN OPIOID AGENT
    Publication number: 20160287573
    Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.
    Type: Application
    Filed: March 31, 2016
    Publication date: October 6, 2016
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Shaoling Li, Manshiu Leung, Hao Zhang, Venkat R. Thalladi, Yun Mo